RT Journal Article
SR Electronic
T1 A new lineage nomenclature to aid genomic surveillance of dengue virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.16.24307504
DO 10.1101/2024.05.16.24307504
A1 Hill, Verity
A1 Cleemput, Sara
A1 Fonseca, Vagner
A1 Tegally, Houriiyah
A1 Brito, Anderson F.
A1 Gifford, Robert
A1 Tran, Vi Thuy
A1 Kien, Duong Thi Hue
A1 Huynh, Tuyen
A1 Yacoub, Sophie
A1 Dieng, Idrissa
A1 Ndiaye, Mignane
A1 Balde, Diamilatou
A1 Diagne, Moussa M.
A1 Faye, Oumar
A1 Salvato, Richard
A1 Wallau, Gabriel Luz
A1 Gregianini, Tatiana S.
A1 Godinho, Fernanda M.S.
A1 Vogels, Chantal B.F.
A1 Breban, Mallery I.
A1 Leguia, Mariana
A1 Jagtap, Suraj
A1 Roy, Rahul
A1 Hapuarachchi, Chanditha
A1 Mwanyika, Gaspary
A1 Giovanetti, Marta
A1 Alcantara, Luiz C.J.
A1 Faria, Nuno R.
A1 Carrington, Christine V.F.
A1 Hanley, Kathryn A.
A1 Holmes, Edward C.
A1 Dumon, Wim
A1 de Oliveira, Tulio
A1 Grubaugh, Nathan D.
YR 2024
UL http://medrxiv.org/content/early/2024/05/17/2024.05.16.24307504.abstract
AB Dengue virus (DENV) is currently causing epidemics of unprecedented scope in endemic settings and expanding to new geographical areas. It is therefore critical to track this virus using genomic surveillance. However, the complex patterns of viral genomic diversity make it challenging to use the existing genotype classification system. Here we propose adding two sub-genotypic levels of virus classification, named major and minor lineages. These lineages have high thresholds for phylogenetic distance and clade size, rendering them stable between phylogenetic studies. We present an assignment tool to show that the proposed lineages are useful for regional, national and sub-national discussions of relevant DENV diversity. Moreover, the proposed lineages are robust to classification using partial genome sequences. We provide a standardized neutral descriptor of DENV diversity with which we can identify and track lineages of potential epidemiological and/or clinical importance. Information about our lineage system, including methods to assign lineages to sequence data and propose new lineages, can be found at: dengue-lineages.org.Competing Interest StatementSC and WD are affiliated with emweb. NDG is a paid consultant for BioNTech. Funding StatementThis publication was made possible by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award Number DP2AI176740 (NDG), CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science (NCATS), a component of the NIH (CBFV), NIH Award Number 1 U01 AI151807-01 (KAH), Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS/FIOCRUZ 13/2022 - REDE SAUDE-RS, grant process 23/2551-0000510-7 and FAPERGS 14/2022 - ARD/ARC, grant process 23/2551-0000852-1), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) through their productivity research fellowships (307209/2023-7; GLW), European Union's Horizon 2020 research and innovation programme under grant agreement No 101000570, and the Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards (IRB) from the Yale University Human Research Protection Program determined that pathogen genomic sequencing of de-identified remnant diagnostic samples as conducted in this study is not research involving human subjects (Yale IRB Protocol ID: 2000033281).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll sequences used to design the lineage system are from Genbank and GISAID, accession numbers in Table S2. Custom scripts and alignments of representative sequences from Genbank can be found on our github (https://github.com/DENV-lineages/lineages-paper). Sequences for the Vietnam case study can be found on Genbank under accession numbers PP269455-PP270050, in bioproject PRJNA1072696. For the case study from Tanzania, sequences were drawn from (Kelly et al. 2023), and can be found on Genbank under accession numbers OM920035-OM920066 for DENV-3 and OM920075-OM920415 for DENV-1. Sequences for the Brazil and Senegal case studies are currently private awaiting separate publications, but are available on request from richard-salvato{at}saude.rs.gov.br and idrissa.dieng{at}pasteur.sn, respectively. https://github.com/DENV-lineages/lineages-paper